M&A Deal Summary

Lupin Acquires GAVIS Pharmaceuticals

On March 9, 2016, Lupin acquired life science company GAVIS Pharmaceuticals

Acquisition Highlights
  • This is Lupin’s 6th transaction in the Life Science sector.
  • This is Lupin’s 2nd transaction in the United States.
  • This is Lupin’s 2nd transaction in New Jersey.

M&A Deal Summary
Date 2016-03-09
Target GAVIS Pharmaceuticals
Sector Life Science
Buyer(s) Lupin
Deal Type Add-on Acquisition

Target

GAVIS Pharmaceuticals

Somerset, New Jersey, United States
GAVIS Pharmaceuticals LLC is a provider of pharmaceutical products in a variety of dosage forms.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lupin

Mumbai, India
Category Company
Founded 1968
Sector Life Science
Employees19,210
Revenue 196.6B INR (2024)
DESCRIPTION

Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. Lupin was founded in 1968 and is based in Mumbai, India.

DEAL STATS #
Overall 7 of 9
Sector (Life Science) 6 of 8
Type (Add-on Acquisition) 5 of 6
State (New Jersey) 2 of 3
Country (United States) 2 of 4
Year (2016) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-09 Novel Laboratories

Somerset, New Jersey, United States

Novel Laboratories, Inc. is a pharmaceutical company.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-10-11 Symbiomix Therapeutics

Newark, New Jersey, United States

Symbiomix Therapeutics is a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. Symbiomix Therapeutics was founded in 2012 and is based in Newark, New Jersey.

Buy $150M
Mergr

Product

Company

Legal